The group is expanding its mRNA-4359 trial to include first-line melanoma.
ApexOnco Front Page
Recent articles
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
AVZO-023 follows AVZO-021 into clinical trials.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
